Medications

Subcutaneous mAb may benefit high-risk outpatients with COVID-19

For high-risk outpatients with mild-to-moderate COVID-19, subcutaneously administered monoclonal antibody (mAb) treatment with casirivimab and imdevimab is associated with reduced risk for 28-day hospitalization or death ...

Medical research

Ivermectin does not prevent progression to severe COVID-19

Ivermectin treatment during early illness does not prevent progression to severe disease for high-risk patients with mild-to-moderate COVID-19, according to a study published online Feb. 18 in JAMA Internal Medicine.

Diseases, Conditions, Syndromes

Unvaccinated have highest SARS-CoV-2 incidence, hospitalization

(HealthDay)—Severe acute respiratory syndrome coronavirus 2 incidence and hospitalization rates are consistently higher for unvaccinated persons, and rates are lowest for those fully vaccinated with a booster, according ...

Diseases, Conditions, Syndromes

COVID-19 hospitalization costs, outcomes in 2020 improved over time

A new study published in Advances in Therapy provides the first comprehensive analysis of the hospitalization costs for COVID-19 patients, factors associated with costs and length of stay, and the monthly trends of costs ...

page 8 from 34